Obviously, RCTs last too short to exert all beneficial metabolic (decreased body weight, improved insulin sensitivity) and anti-inflammatory effects of SGLT-2 inhibitors in terms of cancer risk. The gene discussed is SLC5A2; the disease is cancer.